198 related articles for article (PubMed ID: 28887614)
1. The pro-fibrotic connective tissue growth factor (CTGF/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle.
Morales MG; Acuña MJ; Cabrera D; Goldschmeding R; Brandan E
J Cell Commun Signal; 2018 Mar; 12(1):413-421. PubMed ID: 28887614
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2).
Morales MG; Cabrera D; Céspedes C; Vio CP; Vazquez Y; Brandan E; Cabello-Verrugio C
Cell Tissue Res; 2013 Jul; 353(1):173-87. PubMed ID: 23673415
[TBL] [Abstract][Full Text] [Related]
3. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
[TBL] [Abstract][Full Text] [Related]
4. Connective tissue cells expressing fibro/adipogenic progenitor markers increase under chronic damage: relevance in fibroblast-myofibroblast differentiation and skeletal muscle fibrosis.
Contreras O; Rebolledo DL; Oyarzún JE; Olguín HC; Brandan E
Cell Tissue Res; 2016 Jun; 364(3):647-660. PubMed ID: 26742767
[TBL] [Abstract][Full Text] [Related]
5. Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2.
Mezzano V; Cabrera D; Vial C; Brandan E
J Cell Commun Signal; 2007 Dec; 1(3-4):205-17. PubMed ID: 18600480
[TBL] [Abstract][Full Text] [Related]
6. CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases.
Gonzalez D; Brandan E
Mol Neurobiol; 2019 Aug; 56(8):5911-5916. PubMed ID: 30689195
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Pathological Activities of CCN2/CTGF in Muscle Dystrophy.
Acuña MJ; Brandan E
Methods Mol Biol; 2017; 1489():513-521. PubMed ID: 27734402
[TBL] [Abstract][Full Text] [Related]
8. Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β.
Rebolledo DL; González D; Faundez-Contreras J; Contreras O; Vio CP; Murphy-Ullrich JE; Lipson KE; Brandan E
Matrix Biol; 2019 Sep; 82():20-37. PubMed ID: 30716392
[TBL] [Abstract][Full Text] [Related]
9. Driving fibrosis in neuromuscular diseases: Role and regulation of Connective tissue growth factor (CCN2/CTGF).
Rebolledo DL; Lipson KE; Brandan E
Matrix Biol Plus; 2021 Aug; 11():100059. PubMed ID: 34435178
[TBL] [Abstract][Full Text] [Related]
10. Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis.
Riquelme-Guzmán C; Contreras O; Brandan E
Am J Physiol Cell Physiol; 2018 Apr; 314(4):C415-C427. PubMed ID: 29351412
[TBL] [Abstract][Full Text] [Related]
11. Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy.
Au CG; Butler TL; Sherwood MC; Egan JR; North KN; Winlaw DS
Int J Exp Pathol; 2011 Feb; 92(1):57-65. PubMed ID: 21121985
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model.
Gonzalez D; Rebolledo DL; Correa LM; Court FA; Cerpa W; Lipson KE; van Zundert B; Brandan E
Hum Mol Genet; 2018 Aug; 27(16):2913-2926. PubMed ID: 29860398
[TBL] [Abstract][Full Text] [Related]
13. VEGF induces stress fiber formation in fibroblasts isolated from dystrophic muscle.
Gutpell KM; Hoffman LM
J Cell Commun Signal; 2015 Dec; 9(4):353-60. PubMed ID: 26219981
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.
Cabello-Verrugio C; Morales MG; Cabrera D; Vio CP; Brandan E
J Cell Mol Med; 2012 Apr; 16(4):752-64. PubMed ID: 21645240
[TBL] [Abstract][Full Text] [Related]
15. Low Six4 and Six5 gene dosage improves dystrophic phenotype and prolongs life span of mdx mice.
Yajima H; Kawakami K
Dev Growth Differ; 2016 Aug; 58(6):546-61. PubMed ID: 27224259
[TBL] [Abstract][Full Text] [Related]
16. Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in injured skeletal muscle.
Petrosino JM; Leask A; Accornero F
FASEB J; 2019 Feb; 33(2):2047-2057. PubMed ID: 30216109
[TBL] [Abstract][Full Text] [Related]
17. CTGF/CCN2 exerts profibrotic action in myoblasts via the up-regulation of sphingosine kinase-1/S1P3 signaling axis: Implications in the action mechanism of TGFβ.
Bruno G; Cencetti F; Pertici I; Japtok L; Bernacchioni C; Donati C; Bruni P
Biochim Biophys Acta; 2015 Feb; 1851(2):194-202. PubMed ID: 25457224
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse.
Gibertini S; Zanotti S; Savadori P; Curcio M; Saredi S; Salerno F; Andreetta F; Bernasconi P; Mantegazza R; Mora M
Cell Tissue Res; 2014 May; 356(2):427-43. PubMed ID: 24723230
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation.
Vial C; Zúñiga LM; Cabello-Verrugio C; Cañón P; Fadic R; Brandan E
J Cell Physiol; 2008 May; 215(2):410-21. PubMed ID: 18064627
[TBL] [Abstract][Full Text] [Related]
20. Klotho gene silencing promotes pathology in the mdx mouse model of Duchenne muscular dystrophy.
Wehling-Henricks M; Li Z; Lindsey C; Wang Y; Welc SS; Ramos JN; Khanlou N; Kuro-O M; Tidball JG
Hum Mol Genet; 2016 Jun; 25(12):2465-2482. PubMed ID: 27154199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
